Recent Quotes View Full List My Watchlist Create Watchlist Indicators DJI Nasdaq Composite SPX Gold Crude Oil Hydroworld Market Index Markets Stocks ETFs Tools Overview News Currencies International Treasuries Sunshine Biopharma (NQ: SBFM ) 3.010 +0.080 (+2.73%) Streaming Delayed Price Updated: 4:00 PM EDT, Aug 27, 2024 Add to My Watchlist Quote Overview Detailed Quote Charting Historical Prices News All News News Headlines Press Releases Research Quarterly Reports Insider Filings Other Filings Press Releases about Sunshine Biopharma Sunshine Biopharma Has Launched Nine New Generic Prescription Drugs in 2024: Now Marketing Sixty-One Generic Drugs in Canada August 26, 2024 Via ACCESSWIRE Sunshine Biopharma Reports 2024 Second Quarter Results: Second QTR Revenues up 67%, YTD Revenues up 61% August 19, 2024 Via ACCESSWIRE Sunshine Biopharma Announces Reverse Stock Split August 06, 2024 Via ACCESSWIRE Sunshine Biopharma Reports 2024 First Quarter Results: Revenues Up 54% May 21, 2024 Via ACCESSWIRE Sunshine Biopharma Reports Operating Results for the Fiscal Year Ended December 31, 2023 April 01, 2024 Via ACCESSWIRE Insider Buying: Sunshine Biopharma Inc. (NASDAQ: SBFM) Chief Financial Officer Purchases Shares December 27, 2022 To learn more about Sunshine Biopharma, download the latest research report here Via TheNewswire.com Exposures COVID-19 NASDAQ: SBFM 👥 Enters Into A Collaboration Agreement For Its K1.1 Anticancer mRNA Project! 🔬 November 23, 2022 Christine Petraglia - TraDigital IR Via TheNewswire.com Sunshine Biopharma's Nora Pharma Receives Health Canada Approval for Niopeg(R), a Biosimilar of Neulasta(R) April 19, 2024 Via ACCESSWIRE Sunshine Biopharma Announces Reverse Stock Split April 12, 2024 Via ACCESSWIRE BioMedNewsBreaks — Sunshine Biopharma Inc. (NASDAQ: SBFM) Closes on $10M Public Offering February 15, 2024 Via Investor Brand Network Exposures COVID-19 Sunshine Biopharma, Inc. Announces Pricing of $10.0 Million Underwritten Public Offering February 13, 2024 Via ACCESSWIRE Sunshine Biopharma Reports 2023 Third Quarter Results: Revenues up Significantly Over Last Year Due to a Key Acquisition November 13, 2023 Via ACCESSWIRE Aegis Capital Corp. Acted as Exclusive Placement Agent on a $5.0 Million Private Placement Priced At-the-Market for Sunshine Biopharma, Inc. (NASDAQ:SBFM) May 16, 2023 Via ACCESSWIRE Coronavirus Vaccine Market To Surpass $95 Billion By 2028 February 28, 2023 EQNX::TICKER_START (NASDAQ:SBFM),(NASDAQ:MRNA),(NASDAQ:NVAX),(NASDAQ:VIR),(NASDAQ:INO) EQNX::TICKER_END Via FinancialNewsMedia Exposures COVID-19 SUNSHINE BIOPHARMA SIGNS EXCLUSIVE WORLDWIDE LICENSE WITH UNIVERSITY OF ARIZONA FOR PLpro-BASED COVID-19 TREATMENT February 28, 2023 Montreal – February 28, 2023 – Sunshine Biopharma Inc. (NASDAQ: SBFM), a pharmaceutical company offering and researching life-saving medicines in a variety of therapeutic areas including oncology and... Via FinancialNewsMedia Exposures COVID-19 Product Safety Chinese Lockdown Effects Ripple Marketwide; A Solution Urgently Needed December 08, 2022 Read the latest report on Sunshine Biopharma here. Via TheNewswire.com Exposures COVID-19 One in Five Americans Who Have Been Infected With the Virus Said to Have Long COVID November 17, 2022 Palm Beach, FL – November 17, 2022 – FinancialNewsMedia.com News Commentary – Since the beginning of the pandemic, the critical effort of researchers is to understand how coronavirus damages the body.... Via FinancialNewsMedia Exposures COVID-19 Aegis Capital Corp. acted as Exclusive Placement Agent on a $19.5 Million Private Placement Priced At-the-Market for Sunshine Biopharma Inc. (NASDAQ: SBFM) April 28, 2022 Our newswire features a comprehensive, flat-fee Press Release service. Generate quality engagement with real-time analytics to improve visibility and expand your influence. From Aegis Capital Corp. Via AccessWire Topics Intellectual Property Exposures COVID-19 Intellectual Property Advanced Immunological and Clinical Trials for Treating Ovarian Cancer Accelerating April 25, 2022 Palm Beach, FL – April 25, 2022 – FinancialNewsMedia.com News Commentary – The formation of mutational cells or tissues in female reproductive organs called ovaries leads to ovarian cancer. Cancer... Via FinancialNewsMedia Topics Intellectual Property Exposures Intellectual Property Aegis Capital Corp. acted as Exclusive Placement Agent on an $8 Million Private Placement for Sunshine Biopharma Inc. (NASDAQ: SBFM) March 15, 2022 NEW YORK, NY / ACCESSWIRE / March 15, 2022 / Aegis Capital Corp. acted as Exclusive Placement Agent on an $8 Million Private Placement for Sunshine Biopharma Inc. (NASDAQ:SBFM) About Sunshine... From Aegis Capital Corp. Via AccessWire Exposures COVID-19 Aegis Capital Corp. acted as Sole Bookrunner on an Uplist of an $8 Million Underwritten Public Offering for Sunshine Biopharma Inc. (NASDAQ: SBFM; SBFMW) February 17, 2022 NEW YORK, NY / ACCESSWIRE / February 17, 2022 / Aegis Capital Corp. acted as Sole Bookrunner on an Uplist of an $8 Million Underwritten Public Offering for Sunshine Biopharma Inc. (NASDAQ:SBFM; SBFMW)... From Aegis Capital Corp. Via AccessWire Exposures COVID-19 Data & News supplied by www.cloudquote.io Stock quotes supplied by Barchart Quotes delayed at least 20 minutes. By accessing this page, you agree to the following Privacy Policy and Terms and Conditions.